Omalizumab + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nasal Polyposis
Conditions
Nasal Polyposis, Asthma
Trial Timeline
Dec 1, 2006 → Dec 1, 2009
NCT ID
NCT01393340About Omalizumab + Placebo
Omalizumab + Placebo is a phase 2 stage product being developed by Novartis for Nasal Polyposis. The current trial status is completed. This product is registered under clinical trial identifier NCT01393340. Target conditions include Nasal Polyposis, Asthma.
What happened to similar drugs?
8 of 20 similar drugs in Nasal Polyposis were approved
Approved (8) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03369704 | Phase 3 | Completed |
| NCT03328897 | Phase 3 | Completed |
| NCT01723072 | Phase 3 | Completed |
| NCT01202903 | Phase 3 | Completed |
| NCT01007149 | Phase 3 | Completed |
| NCT00870584 | Approved | Completed |
| NCT00657891 | Approved | Completed |
| NCT00454051 | Approved | Completed |
| NCT01393340 | Phase 2 | Completed |
| NCT00123630 | Phase 2 | Completed |
Competing Products
20 competing products in Nasal Polyposis